Lantheus on Phase 3 Pivotal Trial in Castration-Resistant Prostate Cancer

 Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival

Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses

Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P)

Interim Overall Survival Crossover Adjusted Hazard Ratio was <1.00 when Assessed Using Two-Stage and Inverse Probability Censoring Weighting Methods

Overall Survival data continue to mature, an update is expected once data are available for 75% of protocol-specified target OS events

https://www.marketscreener.com/quote/stock/LANTHEUS-HOLDINGS-INC-17053982/news/Lantheus-Presents-Results-from-the-Primary-Analysis-of-Phase-3-Pivotal-SPLASH-Trial-in-PSMA-Positive-47872510/